<SEC-DOCUMENT>0001144204-19-038572.txt : 20190808
<SEC-HEADER>0001144204-19-038572.hdr.sgml : 20190808
<ACCEPTANCE-DATETIME>20190808161904
ACCESSION NUMBER:		0001144204-19-038572
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190808
DATE AS OF CHANGE:		20190808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		191009797

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv527012_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): </B>August 8, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>SYNTHETIC
BIOLOGICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 36%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 &ndash; Results of Operations
and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2019,
Synthetic Biologics, Inc., a Nevada corporation (the &ldquo;Registrant&rdquo;) issued a press release that included financial information
for its quarter ended June 30, 2019. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information
contained in the press release is being furnished to the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) and
shall not be deemed incorporated by reference into any of the Registrant&rsquo;s registration statements or other filings with
the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&ndash;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="tv527012_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1 Press Release issued by Synthetic Biologics, Inc., dated August 8, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 8, 2019</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 39%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">and Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: center"><A HREF="tv527012_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="tv527012_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Synthetic Biologics, Inc., dated August 8, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



                           <P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv527012_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports Second Quarter
2019 Operational Highlights and Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Announced Clinical Trial Agreement
with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic
Cell Transplant Recipients --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Conference Call Today, August 8,
2019, at 4:30 p.m. (ET) --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, August 8, 2019 &ndash;</B></FONT> <U>Synthetic Biologics, Inc.</U> <FONT STYLE="color: windowtext">(NYSE American: SYN), </FONT>a
late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients,
<FONT STYLE="color: windowtext">today provided an operational update and reported financial results for the three months ended
June 30, 2019. The Company also announced today a clinical trial agreement with Washington University School of Medicine in St.
Louis (&ldquo;Washington University&quot;) to conduct a Phase 1b/2a clinical trial of SYN-004 (ribaxamase), with enrollment expected
to begin in the first quarter of 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext">&ldquo;Our
clinical trial collaboration with Washington University is an important step in our pursuit of a more cost-effective development
strategy for SYN-004 targeting a more specialized patient population,&rdquo; stated Steven A. Shallcross, Chief Executive and Financial
Officer. &ldquo;</FONT>SYN-004&rsquo;s unique mechanism of action designed to degrade intravenous (IV) beta-lactam antibiotics
and prevent dysbiosis of the gut microbiome has the potential to significantly improve outcomes for patients who undergo allogeneic
hematopoietic cell transplantation (HCT), an area of significant unmet medical need.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Prompt initiation of broad-spectrum
IV beta-lactam antibiotics at onset of fever after conditioning chemotherapy for allogenic HCT is a life-saving intervention. However,
this causes significant disruption of the microbiome, which places these patients at very high risk for infection due to some of
our greatest antibiotic resistant threats, such as <I>Clostridioides difficile</I>, vancomycin-resistant <I>Enterococci </I>(VRE),
and multidrug-resistant Gram-negative bacteria. We are seeking to determine if coadministration of SYN-004 while the patient is
receiving IV beta-lactam antibiotics will preserve the microbiome and thus mitigate the risk from these threats,&rdquo; said Dr.
Erik R. Dubberke Professor of Medicine and Clinical Director, Transplant Infectious Diseases at Washington University. &ldquo;There
are data to suggest preservation of the microbiome in allogeneic HCT recipients results in improved immune function after HCT as
well. This would further enhance these patients&rsquo; outcomes and quality of life.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Shallcross continued, &ldquo;During
the second quarter, we remained focused on executing our strategy to advance our portfolio of gastrointestinal (GI) and microbiome-focused
clinical programs. We held a highly informative pre-IND meeting with the U.S. Food and Drug Administration (FDA) for our SYN-020
intestinal alkaline phosphatase (IAP) program and clarified the parameters for IND-enabling toxicology studies. These activities
are ongoing and will support our anticipated Investigational New Drug (IND) application which we intend to file promptly during
the first quarter of 2020.&rdquo; Mr. Shallcross concluded, &ldquo;Interest from prospective patients in our investigator-sponsored
Phase 2b clinical trial of SYN-010 in breath-methane positive irritable bowel syndrome with constipation (IBS-C) patients remains
strong. However, after consulting with the investigators at Cedars-Sinai Medical Center, the study sponsor, enrollment has been
extended to accommodate higher than anticipated screen-fail rates. This is, in part, due to errant laxative use during the screening
period that adversely impacts baseline measurements of IBS-C symptoms and breath-methane levels. Rigorous screening and reliable
baseline parameters are critical to all IBS-C clinical trials in order to ensure the possibility of generating a meaningful data
set of the highest quality. At this time, we are discussing with Cedars-Sinai the opportunity for a data read out in the first
half of 2020, extending our previous guidance from the fourth quarter of 2019. We look forward to sharing important updates and
progress for this and all our GI and microbiome-focused clinical programs.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Development and Operational
Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Entered into a Clinical Trial Agreement with Washington University School of Medicine in St. Louis
to conduct a Phase 1b/2a clinical trial of SYN-004 (ribaxamase)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Under the terms of this agreement, Synthetic Biologics will serve as the sponsor of the study and
supply SYN-004 (ribaxamase) and Dr. Dubberke will serve as the principal investigator along with his Washington University colleague
Dr. Mark A. Schroeder, Associate Professor of Medicine, Division of Oncology, Bone Marrow Transplantation and Leukemia,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Enrollment is expected to begin during the first quarter of 2020, contingent upon review by the
FDA and approval of the clinical study protocol by Washington University&rsquo;s Institutional Review Board (IRB),</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The proposed study is a Phase 1b/2a single-center, randomized, double-blinded, placebo-controlled
clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of oral SYN-004 (ribaxamase) in up to 36 adult
allogeneic HCT recipients,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Study participants will be enrolled into three sequential cohorts that will be administered a different
study-assigned IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 (ribaxamase) and four will receive
placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety
Monitoring Committee, which will make a recommendation on whether to proceed to the next IV beta-lactam antibiotic,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The proposed study will also evaluate potential protective effects of SYN-004 (ribaxamase) on the
gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 (ribaxamase)
in allogeneic HCT recipients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Enrollment is ongoing in the Phase 2b investigator-sponsored clinical study of SYN-010, for the
treatment of IBS-C</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The Phase 2b clinical study is being conducted by the Medically Associated Science and Technology
(MAST) Program at Cedars-Sinai Medical Center and is a 12-week, placebo-controlled, double-blind, randomized clinical trial evaluating
two dose strengths of oral SYN-010 (21 mg and 42 mg) in approximately 150 patients diagnosed with IBS-C,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The primary objective for the study will be to determine the efficacy of SYN-010, measured as an
improvement from baseline in the weekly average number of complete spontaneous bowel movements (CSBMs) during the 12-week treatment
period for SYN-010 21 mg and 42 mg daily doses relative to placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Secondary efficacy endpoints for both dose strengths of SYN-010 will measure changes from baseline
in abdominal pain, bloating, stool frequency as well as the use of rescue medication relative to placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A data readout is anticipated in 1H 2020,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Cedars-Sinai Medical Center and Synthetic Biologics are co-funding the study. The patent rights
covering the use of SYN-010 are owned by Cedars-Sinai Medical Center and are exclusively licensed by Cedars-Sinai Medical Center
to Synthetic Biologics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Evaluated potential clinical development strategies to advance SYN-020 (intestinal alkaline phosphatase)
to and through clinical trials targeting areas of significant unmet medical need, including enterocolitis associated with radiation
therapy for cancer</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Held Pre-IND meeting with FDA and clarified the requirements for IND-enabling toxicology studies</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Exploratory study found SYN-020 enhanced 5-FU tumor treatment in a mouse ectopic colon cancer tumor
model. A confirmatory study is ongoing with larger cohort sizes and additional mechanistic endpoints which, if repeated, may allow
for further broadening of the clinical development strategy for this program,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Anticipate filing a US IND application in Q1 2020;</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Continued to exercise prudent cash management and financial stewardship</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Further reduced cash burn, extending projected cash runway to fund operations through at least
the end of Q3 2020;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Quarter Ended June 30, 2019 Financial
Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses decreased
by 27% to $1.0 million for the three months ended June 30, 2019, from $1.4 million for the three months ended June 30, 2018. This
decrease is primarily due to decreased stock-based compensation expense related to forfeitures and decreased options grants, along
with the reduction of investor relations and consulting costs. The charge related to stock-based compensation expense was $59,000
for the three months ended June 30, 2019, compared to $264,000 the three months ended June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased
by 27% to $2.6 million for the three months ended June 30, 2019, from $3.6 million for the three months ended June 30, 2018. This
decrease is primarily the result of lower SYN-004 (ribaxamase) indirect program costs for the three months ended June 30, 2019,
including salary and related expense reductions resulting from the 2018 restructuring and the fact that no clinical trial activity
for SYN-004 (ribaxamase) was ongoing during the quarter, offset by an increase in manufacturing costs for SYN-020. The research
and development costs incurred during the quarter were primarily related to the investigator-sponsored Phase 2b clinical study
of SYN-010, a potential Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients, and the continued development
of SYN-020. Research and development expenses also include a charge relating to stock-based compensation expense of $31,000 for
the three months ended June 30, 2019, compared to $293,000 for the three months ended June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $80,000 for the three
months ended June 30, 2019, compared to other income of $789,000 for the three months ended June 30, 2018. Other income for the
three months ended June 30, 2019 is primarily comprised of interest income while the three months ended June 30, 2018 is comprised
of non-cash income of $783,000 from the change in fair value of warrants. The decrease in the fair value of the warrants was due
to the decrease in our stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents as of June 30,
2019 was $21.7 million, a decrease of $7.2 million from December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference
call today, Thursday, August 8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">,
2019, at 4:30 p.m. (ET).</FONT> The dial-in information for the call is as follows, U.S. toll free: +1 888-347-5280 or International:
+1 412-902-4280. Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be
webcast over the Internet at <U>https://www.webcaster4.com/Webcast/Page/1096/31274</U>. An archive of the call will be available
for replay at the same URL, <U>https://www.webcaster4.com/Webcast/Page/1096/31274</U><FONT STYLE="font-size: 10pt">,</FONT> for
90 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients.
The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV)
beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, <I>C. difficile</I> infection (CDI),
overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD)
in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing
organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company
is also advancing SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local
GI and systemic diseases. For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions,
and includes statements that SYN-004&rsquo;s unique mechanism of action designed to degrade IV beta-lactam antibiotics and prevent
dysbiosis of the gut microbiome has the potential to significantly improve outcomes for patients who undergo allogeneic hematopoietic
cell transplantation (HCT); data to suggest preservation of the microbiome in allogeneic HCT recipients results in improved immune
function after HCT as well and this further enhancing these patients&rsquo; outcomes and quality of life; an IND for SYN-020 will
be filed during the first quarter of 2020; enrollment for the Phase 1b/2a clinical trial of SYN-004 is expected to begin during
the first quarter of 2020, contingent upon approval of the clinical study protocol by the Washington University School of Medicine&rsquo;s
Institutional Review Board (IRB) and the FDA; a data readout for the Phase 2b investigator-sponsored clinical study of SYN-010
for the treatment of IBS-C is anticipated in 1H 2020</I>; <I>and extending Synthetic Biologics&rsquo; projected cash runway through
at least the end of Q3 2020. These forward-looking statements are based on management's expectations and assumptions as of the
date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that
could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include,
among others, the ability of Synthetic Biologics&rsquo; product candidates to demonstrate safety and effectiveness, as well as
results that are consistent with prior results, Synthetic Biologics' clinical trials continuing enrollment as expected, a failure
to receive the necessary regulatory approvals for commercialization of Synthetic Biologics' therapeutics, including approval of
proposed trial designs, a failure of Synthetic Biologics' clinical trials, and those conducted by investigators, for SYN-004, SYN-010
and SYN-020 to be commenced or completed on time or to achieve desired results and benefits, a failure to file INDs when anticipated,
a failure of Synthetic Biologics' clinical trials to continue enrollment as expected or receive anticipated funding, a failure
of Synthetic Biologics to successfully develop, market or sell its products, Synthetic Biologics' inability to maintain its material
licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize products, Synthetic
Biologics&rsquo; ability to achieve acceptance of its product candidates in the marketplace and the successful development, marketing
or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete or non-competitive,
Synthetic Biologics' ability to continue to comply with the continued listing requirements of the NYSE American, the continued
maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming and remaining profitable, Synthetic
Biologics' ability to obtain or maintain the capital or grants necessary to fund its research and development activities, a loss
of any of Synthetic Biologics' key scientists or management personnel and other factors described in Synthetic Biologics' Form
10-K and 10-K/A for the year ended December 31, 2018 and its other filings with the SEC, including subsequent periodic reports
on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics
undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future
events, or otherwise, except as required by law.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>For further information, please contact:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240)
660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Synthetic Biologics, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>(in thousands, except share and per share amounts)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif">Consolidated Balance Sheets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Cash and cash equivalents</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">21,712</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">28,918</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,298</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">593</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">485</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.75pt">Right of use asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">481</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,999</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,141</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholder&rsquo;s Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,412</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,686</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Series A Convertible Preferred Stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,419</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,296</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Total stockholder&rsquo;s equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,168</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,159</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,999</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,141</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Operations</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended June 30</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,044</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,431</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,594</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,572</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,638</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,003</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,638</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,003</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Change in fair value of warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">783</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Other Income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">789</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net Loss </B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,558</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,214</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to Non-controlling Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(17</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net Loss Attributable to Synthetic Biologics, Inc. </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>and Subsidiaries</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,531</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,197</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 4.6pt">Series A Preferred Stock Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(61</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(61</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 4.6pt">Series B Preferred Stock Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(117</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 0.1pt">Net Loss Attributable to Common Stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,709</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,258</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.16</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,465,314</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,683,383</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !; 4 # 2(  A$! Q$!_\0
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M\;>5=:?.8M]I<VTC+)#/&QEBF0.Q*D"OR.^(/[!OQ?\ "45S>^$-0T3XB:9
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M=*\3Z)?^*M&\/7]Q?JE_J.B:]8V%U"R27&E%X9D<JLOQSXY_:C_:]_X(.?\
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M:>+D_;U;<\[*]W&%I.TFG:VR:6BO;^@;]EK_ (.D/$5Q\2-"\%_MP_L\^$_
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MA3O"ME0/G57&& -?J5_P7Z7;_P $J?VEB"2 GP_D ;^^/B#X==F_V2SG+;2
M0-GW20>''U,)4SY4ZV"C44YPIU)1JJFVYNE:5EJG%/ELK+5WU1O@XXB&4JI0
MQ#HV4ZD$X>U:45)\K?5/>[NTTDM-#B_^"-7_  5@^)7_  4WNOVAH/B)\&?
MGPG_ .%++\-#I7_"%>,?$?BK^VW\=#QD+Q+^/Q!HNBM9+IT?AJU6![1)8[AK
MNY\[88XB?EO_ (*/_P#!QIX%_95^*WBC]G[]F/X5:9\?OB3X"U%M!^(OCOQ5
MXGNO#GPC\(^*K<(MYX.T2+0++4O$WCOQ%ITTBP:X;>7PYH.GWH33++7-8O\
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M8_!T\1[2& Q.#=;#KB#A^%26'E@*U+,,&ESRE4_GB-\6XW$@C!YP",'<.0<
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M-JSE)-Z[V25E9K"X2=&O6QF+G2]I/=T^?DC34;23YHIW:5D[.UFVWN?P1_\
M!QQ^S9J?[.'[>OA']I7P5%<Z'H'[1NC67CO3M;TN-H5TKXT_">33;3Q//;W
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M^(O@4:I<V-AXBT2ZM[71O%WAVZ2]33-6M5N=/%W:WMI?QV']T7PZ_P""4?\
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M)*5.JE*$\13KPJ252-G]&T445_?9_"H4444 (0",$ @]01D'\#2;5X^5>.G
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MD JV?K>%\5B<)Q?QSEV/PF<QGC<[I9GE.*KY7C:&35LMP_#7#^%Q$L-FE2^
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M,A5K[5"@WQ,K[" I*YVC:N> "/UG96:.&,_?6)8Y6P22WE!55L DC)8DDC:
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MXK+I5*56M3;O"&*@JD\#C(<EE*EC,%C(*-X0J1CJOI>*N N'..,FJY%Q?E&
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;I-K9_._IOK^5M3R+*R225FGI^7S"BBBF!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
